Walleye Capital
AVBP icon

Walleye Capital’s ArriVent BioPharma AVBP Stock Holding History

Walleye Capital’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,115
Closed -$445K – 5090
2025
Q4 		$445K Sell
22,115
-5,653
-20% -$118K ﹤0.01% 3028
2025
Q3 		$512K Buy
27,768
+18,314
+194% +$360K ﹤0.01% 2588
2025
Q2 		$206K Buy
+9,454
New +$196K ﹤0.01% 3349
2024
Q3 		– Sell
-25,000
Closed -$464K – 5956
2024
Q2 		$464K Hold
25,000
– – ﹤0.01% 3570
2024
Q1 		$447K Buy
+25,000
New +$504K ﹤0.01% 3295

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Walleye Capital's AVBP Position: Q1 2026 in Review

Walleye Capital sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 22,115 shares — an estimated $445K sold.

Walleye Capital first reported a position in AVBP in Q1 2024 and held it in 5 quarters. The position peaked at $512K in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Walleye Capital reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 22,115 ArriVent BioPharma shares in Q1 2026, an estimated $445K.
  • Walleye Capital first reported a position in ArriVent BioPharma in Q1 2024 and held it in 5 quarters.
  • Walleye Capital's ArriVent BioPharma position peaked at $512K in Q3 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.